227 results on '"Vandenbroeck, Koen"'
Search Results
202. Identification of a functional variant in the KIF5A-CYP27B1-METTL1-FAM119B locus associated with multiple sclerosis.
- Author
-
Alcina A, Fedetz M, Fernández O, Saiz A, Izquierdo G, Lucas M, Leyva L, García-León JA, Abad-Grau Mdel M, Alloza I, Antigüedad A, Garcia-Barcina MJ, Vandenbroeck K, Varadé J, de la Hera B, Arroyo R, Comabella M, Montalban X, Petit-Marty N, Navarro A, Otaegui D, Olascoaga J, Blanco Y, Urcelay E, and Matesanz F
- Subjects
- Chromosome Mapping, Chromosomes, Human, Pair 12, Enhancer Elements, Genetic, Genome-Wide Association Study, Humans, Multiple Sclerosis metabolism, Polymorphism, Single Nucleotide, Transcription, Genetic, 25-Hydroxyvitamin D3 1-alpha-Hydroxylase genetics, Genetic Predisposition to Disease, Kinesins genetics, Methyltransferases genetics, Multiple Sclerosis genetics, Quantitative Trait Loci
- Abstract
Background and Aim: Several studies have highlighted the association of the 12q13.3-12q14.1 region with coeliac disease, type 1 diabetes, rheumatoid arthritis and multiple sclerosis (MS); however, the causal variants underlying diseases are still unclear. The authors sought to identify the functional variant of this region associated with MS., Methods: Tag-single nucleotide polymorphism (SNP) analysis of the associated region encoding 15 genes was performed in 2876 MS patients and 2910 healthy Caucasian controls together with expression regulation analyses., Results: rs6581155, which tagged 18 variants within a region where 9 genes map, was sufficient to model the association. This SNP was in total linkage disequilibrium (LD) with other polymorphisms that associated with the expression levels of FAM119B, AVIL, TSFM, TSPAN31 and CYP27B1 genes in different expression quantitative trait loci studies. Functional annotations from Encyclopedia of DNA Elements (ENCODE) showed that six out of these rs6581155-tagged-SNPs were located in regions with regulatory potential and only one of them, rs10877013, exhibited allele-dependent (ratio A/G=9.5-fold) and orientation-dependent (forward/reverse=2.7-fold) enhancer activity as determined by luciferase reporter assays. This enhancer is located in a region where a long-range chromatin interaction among the promoters and promoter-enhancer of several genes has been described, possibly affecting their expression simultaneously., Conclusions: This study determines a functional variant which alters the enhancer activity of a regulatory element in the locus affecting the expression of several genes and explains the association of the 12q13.3-12q14.1 region with MS.
- Published
- 2013
- Full Text
- View/download PDF
203. Allelic combinations of immune-response genes as possible composite markers of IFN-β efficacy in multiple sclerosis patients.
- Author
-
Kulakova OG, Tsareva EY, Boyko AN, Shchur SG, Gusev EI, Lvovs D, Favorov AV, Vandenbroeck K, and Favorova OO
- Subjects
- Gene Frequency immunology, Genetic Loci immunology, Genotype, Humans, Multiple Sclerosis immunology, Polymorphism, Single Nucleotide immunology, Receptor, Interferon alpha-beta genetics, Receptor, Interferon alpha-beta immunology, Receptors, CCR5 genetics, Receptors, CCR5 immunology, Transforming Growth Factor beta1 genetics, Transforming Growth Factor beta1 immunology, Alleles, Interferon-beta immunology, Interferon-beta therapeutic use, Multiple Sclerosis drug therapy, Multiple Sclerosis genetics
- Abstract
Background: IFN-β is widely used as the first-line disease-modifying treatment for multiple sclerosis. However, 30-50% of multiple sclerosis patients do not respond to this therapy. Identification of genetic variants and their combinations that predict responsiveness to IFN-β could be useful for treatment prognosis., Materials & Methods: The combinations of alleles of nine polymorphic loci in immune-response genes were analyzed in 253 Russian multiple sclerosis patients as possible determinants of clinically optimal IFN-β treatment response using APSampler software., Results: Carriage of TGFB1*-509C and CCR5*d was associated with favorable IFN-β response by itself. CCR5*d, IFNAR1*16725G, IFNG*874T and IFNB1*153T/T were the components of the combinations, associated with clinically optimal response to IFN-β. Carriage of composite markers (CCR5*d + IFNAR1*G + IFNB1*T/T) or (CCR5*d + IFNAR1*G + IFNG*T) is beneficial for IFN-β treatment efficacy., Discussion: The data obtained provides evidence of the cumulative effect of immune-response genes on IFN-β treatment efficacy. This joint contribution may reflect the additive effect of independent allelic variants and epistatic interactions between some of them.
- Published
- 2012
- Full Text
- View/download PDF
204. Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29 000 subjects.
- Author
-
Lill CM, Liu T, Schjeide BM, Roehr JT, Akkad DA, Damotte V, Alcina A, Ortiz MA, Arroyo R, Lopez de Lapuente A, Blaschke P, Winkelmann A, Gerdes LA, Luessi F, Fernadez O, Izquierdo G, Antigüedad A, Hoffjan S, Cournu-Rebeix I, Gromöller S, Faber H, Liebsch M, Meissner E, Chanvillard C, Touze E, Pico F, Corcia P, Dörner T, Steinhagen-Thiessen E, Baeckman L, Heekeren HR, Li SC, Lindenberger U, Chan A, Hartung HP, Aktas O, Lohse P, Kümpfel T, Kubisch C, Epplen JT, Zettl UK, Fontaine B, Vandenbroeck K, Matesanz F, Urcelay E, Bertram L, and Zipp F
- Subjects
- Databases, Genetic, Humans, Polymorphism, Single Nucleotide genetics, Risk Factors, White People genetics, Apolipoproteins E genetics, Genetic Association Studies, Genetic Predisposition to Disease, Multiple Sclerosis genetics
- Abstract
Background: Single nucleotide polymorphisms (SNPs) rs429358 (ε4) and rs7412 (ε2), both invoking changes in the amino-acid sequence of the apolipoprotein E (APOE) gene, have previously been tested for association with multiple sclerosis (MS) risk. However, none of these studies was sufficiently powered to detect modest effect sizes at acceptable type-I error rates. As both SNPs are only imperfectly captured on commonly used microarray genotyping platforms, their evaluation in the context of genome-wide association studies has been hindered until recently., Methods: We genotyped 12 740 subjects hitherto not studied for their APOE status, imputed raw genotype data from 8739 subjects from five independent genome-wide association studies datasets using the most recent high-resolution reference panels, and extracted genotype data for 8265 subjects from previous candidate gene assessments., Results: Despite sufficient power to detect associations at genome-wide significance thresholds across a range of ORs, our analyses did not support a role of rs429358 or rs7412 on MS susceptibility. This included meta-analyses of the combined data across 13 913 MS cases and 15 831 controls (OR=0.95, p=0.259, and OR 1.07, p=0.0569, for rs429358 and rs7412, respectively)., Conclusion: Given the large sample size of our analyses, it is unlikely that the two APOE missense SNPs studied here exert any relevant effects on MS susceptibility.
- Published
- 2012
- Full Text
- View/download PDF
205. Replication study of 10 genes showing evidence for association with multiple sclerosis: validation of TMEM39A, IL12B and CBLB [correction of CLBL] genes.
- Author
-
Varadé J, Comabella M, Ortiz MA, Arroyo R, Fernández O, Pinto-Medel MJ, Fedetz M, Izquierdo G, Lucas M, Gómez CL, Rabasa AC, Alcina A, Matesanz F, Alloza I, Antigüedad A, García-Barcina M, Otaegui D, Olascoaga J, Saiz A, Blanco Y, Montalbán X, Vandenbroeck K, and Urcelay E
- Subjects
- Adult, Female, Genome-Wide Association Study, Genotype, Humans, Male, Polymorphism, Single Nucleotide, Adaptor Proteins, Signal Transducing genetics, Genetic Predisposition to Disease genetics, Interleukin-12 Subunit p40 genetics, Membrane Proteins genetics, Multiple Sclerosis genetics, Proto-Oncogene Proteins c-cbl genetics
- Abstract
Background and Objectives: Ten genes previously showing different evidence of association with multiple sclerosis have been selected to validate., Methods: Eleven polymorphisms were genotyped with the iPLEX™ Sequenom in a well-powered collection of Spanish origin including 2863 multiple sclerosis cases and 2930 controls., Results: Replication extended to the following polymorphisms: PKN2 (rs305217), GTF2B (rs7538427), EPHA4 (rs1517440), YTHDF3 (rs12115114), ANKFN1 (rs17758761) and PTPRM (rs4798571), which did not reach the threshold of significance in a follow-up of the first genome-wide association study (GWAS) conducted in multiple sclerosis; TMEM39A (rs1132200), which appeared as a newly identified susceptibility gene in the same study; a gene previously reaching GWAS significance in Italy, CBLB (rs9657904); IL12B (rs6887695, rs10045431), a susceptibility gene shared by diverse autoimmune diseases and, finally, another gene showing inconclusive association with multiple sclerosis, CNR1 (rs1049353)., Conclusions: Pooled analysis corroborated the effect on MS predisposition of three genes: TMEM39A [rs1132200: p(M-H)=0.001; OR(M-H) (95% CI)= 0.84 (0.75-0.93)], IL12B [rs6887695: p(M-H)=0.03; OR(M-H) (95% CI)= 1.09 (1.01-1.17)] and CBLB [rs9657904: p(M-H)=0.01; OR(M-H) (95% CI)= 0.89 (0.81-0.97)].
- Published
- 2012
- Full Text
- View/download PDF
206. Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients.
- Author
-
Tsareva EY, Kulakova OG, Boyko AN, Shchur SG, Lvovs D, Favorov AV, Gusev EI, Vandenbroeck K, and Favorova OO
- Subjects
- Adult, Alleles, Biomarkers, Pharmacological blood, Epistasis, Genetic, Female, Genes, MHC Class II genetics, Genetic Association Studies, Glatiramer Acetate, Humans, Male, Middle Aged, Multifactorial Inheritance, Multiple Sclerosis genetics, HLA-DRB1 Chains genetics, Multiple Sclerosis drug therapy, Peptides therapeutic use, Receptor, Interferon alpha-beta genetics, Receptors, CCR5 genetics, Transforming Growth Factor beta1 genetics
- Abstract
Background: Glatiramer acetate (GA) is widely used as a first-line disease-modifying treatment for multiple sclerosis (MS). However, a significant proportion of MS patient appears to experience modest benefit from GA-treatment. Genetic variants affecting the clinical response to GA are believed to be relevant as biomarkers of GA-treatment efficiency., Patients & Methods: Nine polymorphisms in candidate genes were analyzed as possible determinants of GA response in 285 Russian MS patients. Special attention was given to identification of response-associated allelic combinations by means of the APSampler algorithm., Results: No significant associations were found for individual polymorphisms. Alleles DRB1*15, TGFB1*T, CCR5*d and IFNAR1*G were the components of the combinations, of which carriage was significantly higher in nonresponders than in responders. Carriers of the most significant combinations: DRB1*15 + TGFB1*T + CCR5*d + IFNAR1*G and DRB1*15 + TGFB1*T + CCR5*d (permutation p-values: 0.0056 and 0.013, respectively) had a 14 to 15-times increased risk of ineffective response to GA therapy., Discussion: The results suggest that the influence of immune-response genes on GA-induced response has a polygenic nature. The data are interpreted as evidence of additive and epistatic influences of the genes on GA efficiency for MS treatment.
- Published
- 2012
- Full Text
- View/download PDF
207. Pharmacogenomics and multiple sclerosis: moving toward individualized medicine.
- Author
-
Comabella M and Vandenbroeck K
- Subjects
- Antibodies therapeutic use, Humans, Interferon-beta genetics, Interferon-beta immunology, Polymorphism, Single Nucleotide genetics, Precision Medicine trends, Proteomics, Multiple Sclerosis drug therapy, Multiple Sclerosis genetics, Pharmacogenetics, Precision Medicine methods
- Abstract
Notwithstanding the availability of disease-modifying treatments including interferon-β, glatiramer acetate, and natalizumab, a considerable proportion of multiple sclerosis (MS) patients experience continued progression of disease, clinical relapses, disease activity on MRI, and adverse effects. Application of gene expression, proteomic or genomic approaches is universally accepted as a suitable strategy toward the identification of biomarkers with predictive value for beneficial/poor clinical response to therapy and treatment risks. This review focuses on recent progress in research on the pharmacogenomics of disease-modifying therapies for MS. Although MS drug response biomarkers are not yet routinely implemented in the clinic, the diversity of reported, promising molecular markers is rapidly increasing. Even though most of these markers await further validation, given time, this research is likely to empower neurologists with an enhanced armamentarium to facilitate rational decisions on therapy and patient management.
- Published
- 2011
- Full Text
- View/download PDF
208. The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery?
- Author
-
McLaughlin M and Vandenbroeck K
- Subjects
- Antiviral Agents pharmacology, Benzoquinones therapeutic use, Cyclooxygenase 2 Inhibitors metabolism, Drug Discovery, Endoplasmic Reticulum genetics, Endoplasmic Reticulum metabolism, Glucosidases antagonists & inhibitors, Glucosidases metabolism, Humans, Interleukin-12 metabolism, Lactams, Macrocyclic therapeutic use, Molecular Chaperones genetics, Receptors, Mitogen metabolism, Unfolded Protein Response, Benzoquinones pharmacology, Cyclooxygenase 2 Inhibitors pharmacology, Endoplasmic Reticulum drug effects, Lactams, Macrocyclic pharmacology, Molecular Chaperones metabolism, Molecular Targeted Therapy, Protein Folding drug effects, Small Molecule Libraries pharmacology
- Abstract
Cytosolic heat shock proteins have received significant attention as emerging therapeutic targets. Much of this excitement has been triggered by the discovery that HSP90 plays a central role in the maintenance and stability of multifarious oncogenic membrane receptors and their resultant tyrosine kinase activity. Numerous studies have dealt with the effects of small molecules on chaperone- and stress-related pathways of the endoplasmic reticulum (ER). However, unlike cytosolic chaperones, relatively little emphasis has been placed upon translational avenues towards targeting of the ER for inhibition of folding/secretion of disease-promoting proteins. Here, we summarise existing small molecule inhibitors and potential future targets of ER chaperone-mediated inhibition. Client proteins of translational relevance in disease treatment are outlined, alongside putative future disease treatment modalities based on ER-centric targeted therapies. Particular attention is paid to cancer and autoimmune disorders via the effects of the GRP94 inhibitor geldanamycin and its population of client proteins, overloading of the unfolded protein response, and inhibition of members of the IL-12 family of cytokines by celecoxib and non-coxib analogues., (© 2010 The Authors. British Journal of Pharmacology © 2010 The British Pharmacological Society.)
- Published
- 2011
- Full Text
- View/download PDF
209. IFN-beta pharmacogenomics in multiple sclerosis.
- Author
-
Vandenbroeck K, Urcelay E, and Comabella M
- Subjects
- Gene Expression Profiling, Glypicans genetics, Humans, Interferon Type I genetics, Polymorphism, Single Nucleotide, Recombinant Proteins, Interferon Type I therapeutic use, Multiple Sclerosis drug therapy, Multiple Sclerosis genetics, Pharmacogenetics
- Abstract
Multiple sclerosis (MS) is a condition of the CNS marked by inflammation and neurodegeneration. Interferon (IFN)-beta was the first, and still is the main, immunomodulatory treatment for MS. Its clinical efficacy is limited, and a proportion of patients, ranging between 20-55%, do not respond to the therapy. Identification and subsequently, implementation in the clinic of biomarkers predictive for individual therapeutic response would facilitate improved patient care in addition to ensuring a more rational provision of this therapy. In this article, we summarize the main findings from studies addressing the pharmacogenomics of clinical response to IFN-beta in MS by either whole-genome association scans, candidate gene or transcriptomics studies. Whole-genome DNA association screens have revealed a high representation of brain-specific genes, and have hinted toward both extracellular ligand-gated ion channels and type I IFNs pathway genes as important categories of genetic IFN-beta response modifiers. One hit, glypican 5 (GPC5), was recently replicated in an independent study of IFN-beta responsiveness. Recent RNA transcriptomics studies have revealed the occurrence of a pre-existing type I IFN gene-expression signature, composed of genes that are predominantly induced by type I IFNs, as a potential contributing feature of poor response to therapy. Thus, while the outlines of a complex polygenic mechanism are gradually being uncovered, the main challenges for the near future will reside in the robust validation of identified response-modifying genes as well as in the decipherment of the mechanistic relationships between these genes and clinical response to IFN-beta.
- Published
- 2010
- Full Text
- View/download PDF
210. Validation of the CD6 and TNFRSF1A loci as risk factors for multiple sclerosis in Spain.
- Author
-
Swaminathan B, Matesanz F, Cavanillas ML, Alloza I, Otaegui D, Olascoaga J, Cénit MC, de las Heras V, Barcina MG, Arroyo R, Alcina A, Fernandez O, Antigüedad A, Urcelay E, and Vandenbroeck K
- Subjects
- Adolescent, Adult, Aged, Case-Control Studies, Child, Cohort Studies, Europe epidemiology, Female, Genetic Predisposition to Disease epidemiology, Genetic Predisposition to Disease genetics, Genotype, Humans, Male, Middle Aged, Multiple Sclerosis epidemiology, Polymorphism, Single Nucleotide immunology, Risk Factors, Spain epidemiology, Young Adult, Antigens, CD genetics, Antigens, Differentiation, T-Lymphocyte genetics, Genetic Loci genetics, Genetic Loci immunology, Multiple Sclerosis genetics, Multiple Sclerosis immunology, Receptors, Tumor Necrosis Factor, Type I genetics
- Abstract
A recent meta-analysis of genome-wide association screens coupled to a replication exercise in a combined US/UK collection led to the identification of 4 single nucleotide polymorphisms (SNPs) in three gene loci, i.e. TNFRSF1A, CD6 and IRF8, as novel risk factors for multiple sclerosis with genome-wide level of significance. In the present study, using a combined all-Spain collection of 2515 MS patients and 2942 healthy controls, we demonstrate significant association of rs17824933 in CD6 (P(CMH)=0.004; OR=1.14; 95% CI 1.04-1.24) and of rs1860545 in TNFRSF1A (P(CMH)=0.001; OR=1.15; 95% CI 1.06-1.25) with MS, while the low-frequency coding non-synonymous SNP rs4149584 in TNFRSF1A displayed a trend for association (P(CMH)=0.062; OR=1.27; 95% CI 0.99-1.63). This data reinforce a generic role for CD6 and TNFRSF1A in susceptibility to MS, extending to populations of southern European ancestry., (Copyright 2010 Elsevier B.V. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
211. Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients.
- Author
-
O'Doherty C, Favorov A, Heggarty S, Graham C, Favorova O, Ochs M, Hawkins S, Hutchinson M, O'Rourke K, and Vandenbroeck K
- Subjects
- Female, Humans, Ireland, Male, Gene Frequency genetics, Interferon-beta therapeutic use, Multiple Sclerosis drug therapy, Multiple Sclerosis genetics, Polymorphism, Genetic genetics, White People genetics
- Abstract
Introduction: IFN-beta is widely used as first-line immunomodulatory treatment for multiple sclerosis. Response to treatment is variable (30-50% of patients are nonresponders) and requires a long treatment duration for accurate assessment to be possible. Information about genetic variations that predict responsiveness would allow appropriate treatment selection early after diagnosis, improve patient care, with time saving consequences and more efficient use of resources., Materials & Methods: We analyzed 61 SNPs in 34 candidate genes as possible determinants of IFN-beta response in Irish multiple sclerosis patients. Particular emphasis was placed on the exploration of combinations of allelic variants associated with response to therapy by means of a Markov chain Monte Carlo-based approach (APSampler)., Results: The most significant allelic combinations, which differed in frequency between responders and nonresponders, included JAK2-IL10RB-GBP1-PIAS1 (permutation p-value was p(perm) = 0.0008), followed by JAK2-IL10-CASP3 (p(perm) = 0.001)., Discussion: The genetic mechanism of response to IFN-beta is complex and as yet poorly understood. Data mining algorithms may help in uncovering hidden allele combinations involved in drug response versus nonresponse.
- Published
- 2009
- Full Text
- View/download PDF
212. United Europeans for development of pharmacogenomics in multiple sclerosis network.
- Author
-
Vandenbroeck K, Comabella M, Tolosa E, Goertsches R, Brassat D, Hintzen R, Infante-Duarte C, Favorov A, Escorza S, Palacios R, Oksenberg JR, and Villoslada P
- Subjects
- Ethics, Medical, Europe epidemiology, Genome-Wide Association Study, Humans, Intellectual Property, Internet, Multiple Sclerosis epidemiology, Multiple Sclerosis immunology, Multiple Sclerosis therapy, Polymorphism, Genetic, Polymorphism, Single Nucleotide, RNA, Messenger genetics, Research standards, Research trends, Multiple Sclerosis genetics, Pharmacogenetics trends
- Abstract
Multiple sclerosis (MS) is a chronic inflammatory, disabling disease of the CNS. A recent study has estimated the annual cost of MS in Europe at euro12.5 billion. There is no definitive cure for the disease. Immunomodulatory therapies, such as IFN-beta and glatiramer acetate, are only partially effective. Various new therapies in the final stages of clinical trials are being developed in the absence of efficacy biomarkers. Hence, there is a pressing need for identification of MS treatment response biomarkers. The focus of the multicenter research initiative United Europeans for the development of pharmacogenomics in MS (UEPHA*MS) is to promote and improve training opportunities in the novel supradisciplinary area of pharmacogenomics, biomarker research and systems biology applied to MS. UEPHA*MS is a Marie Curie Initial Training network funded by the 7th Framework Programme of the European Commission. The main scientific goals of this network are both to enhance our knowledge of the mechanisms determining response outcomes of existing immunomodulatory therapies and to identify novel therapeutic opportunities. UEPHA*MS is composed of 11 internationally recognized research teams from five countries with an assortment of expertise in complementary disciplines. The UEPHA*MS network will provide a coherent and internationally competitive platform for the training of young scientists based on multidisciplinary state-of-the-art laboratory-based and network-wide activities. This network will be instrumental in priming young scientists for Europe's collective effort toward improved provision of healthcare based on personalized medicine.
- Published
- 2009
- Full Text
- View/download PDF
213. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine.
- Author
-
Hawwa AF, Millership JS, Collier PS, Vandenbroeck K, McCarthy A, Dempsey S, Cairns C, Collins J, Rodgers C, and McElnay JC
- Subjects
- Adolescent, Antimetabolites, Antineoplastic immunology, Antimetabolites, Antineoplastic metabolism, Azathioprine immunology, Azathioprine metabolism, Child, Child, Preschool, Female, Gene Frequency genetics, Genotype, Guanine Nucleotides genetics, Guanine Nucleotides metabolism, Humans, Inflammatory Bowel Diseases enzymology, Male, Mercaptopurine immunology, Mercaptopurine metabolism, Methyltransferases immunology, Methyltransferases metabolism, Pharmacogenetics methods, Polymorphism, Genetic genetics, Precursor Cell Lymphoblastic Leukemia-Lymphoma enzymology, Thionucleotides metabolism, Treatment Outcome, Antimetabolites, Antineoplastic therapeutic use, Azathioprine therapeutic use, Inflammatory Bowel Diseases drug therapy, Mercaptopurine therapeutic use, Methyltransferases therapeutic use, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy
- Abstract
Aims: To examine the allelic variation of three enzymes involved in 6-mercaptopurine/azathioprine (6-MP/AZA) metabolism and evaluate the influence of these polymorphisms on toxicity, haematological parameters and metabolite levels in patients with acute lymphoblastic leukaemia (ALL) or inflammatory bowel disease (IBD)., Methods: Clinical data and blood samples were collected from 19 ALL paediatric patients and 35 IBD patients who were receiving 6-MP/AZA therapy. All patients were screened for seven genetic polymorphisms in three enzymes involved in mercaptopurine metabolism [xanthine oxidase, inosine triphosphatase (C94-->A and IVS2+21A-->C) and thiopurine methyltransferase]. Erythrocyte and plasma metabolite concentrations were also determined. The associations between the various genotypes and myelotoxicity, haematological parameters and metabolite concentrations were determined., Results: Thiopurine methyltransferase variant alleles were associated with a preferential metabolism away from 6-methylmercaptopurine nucleotides (P = 0.008 in ALL patients, P = 0.038 in IBD patients) favouring 6-thioguanine nucleotides (6-TGNs) (P = 0.021 in ALL patients). Interestingly, carriers of inosine triphosphatase IVS2+21A-->C variants among ALL and IBD patients had significantly higher concentrations of the active cytotoxic metabolites, 6-TGNs (P = 0.008 in ALL patients, P = 0.047 in IBD patients). The study confirmed the association of thiopurine methyltransferase heterozygosity with leucopenia and neutropenia in ALL patients and reported a significant association between inosine triphosphatase IVS2+21A-->C variants with thrombocytopenia (P = 0.012). CONCLUSIONS; Pharmacogenetic polymorphisms in the 6-MP pathway may help identify patients at risk for associated toxicities and may serve as a guide for dose individualization.
- Published
- 2008
- Full Text
- View/download PDF
214. Pharmacogenomics of the response to IFN-beta in multiple sclerosis: ramifications from the first genome-wide screen.
- Author
-
Vandenbroeck K and Matute C
- Subjects
- Genome, Human genetics, Humans, Genetic Testing methods, Interferon-beta therapeutic use, Multiple Sclerosis drug therapy, Multiple Sclerosis genetics, Pharmacogenetics methods
- Abstract
Evaluation of: Byun E, Caillier SJ, Montalban X et al.: Genome-wide pharmacogenomic analysis of the response to interferon-beta therapy in multiple sclerosis. Arch. Neurol. 65(3) 337-344 (2008). Specifically, IFN-beta is the most widely used disease-modifying therapy for the treatment of multiple sclerosis. The main benefits of the therapy, fewer and less severe relapses as well as delayed disease progression, are seen in only approximately 50% of the patients. Genetic polymorphisms may constitute in-built determinants of individual differences in response to IFN-beta. Prior attempts to identify such 'predictors of response' were hypothesis-driven in that they were based on preselection of candidate genes associated with Type I interferon pathways. In the present study, the authors performed the first ever nonbiased genome-wide association screen in an attempt to identify response-predictive SNPs. Using a robust four-stage completion strategy coupled to advanced SNP ranking/clustering algorithms, 18 significant SNPs were identified, many of which are located in genes that have never before been linked clearly to Type I interferon biology or therapeutic effects. While this study was not designed per se so as to validate earlier findings, genes arising from previous pharmacogenomic studies were generally not confirmed. This is due to major discrepancies between interstudy sets of used SNPs, but may also reflect differential strategies for ascertainment of response to IFN-beta, or simply Type I/II errors. The 100-K SNP screen by Byun et al. hallmarks a new stage of pharmacogenomics research applied to multiple sclerosis treatments. Through the judicious implementation of DNA pooling on SNP microarrays, it vividly demonstrates that informative genome-wide pharmacogenomic screens can be performed at a fraction of the cost of individual microarray genotyping. Although, unquestionably, higher-density SNP screens and further replication studies are needed, this study is instrumental in bringing the concept of personalized medicine a (small) step closer to the multiple sclerosis patient. In addition, it has generated a flurry of novel information of likely importance in furthering our understanding of Type I interferon biology.
- Published
- 2008
- Full Text
- View/download PDF
215. Interferon gamma allelic variants: sex-biased multiple sclerosis susceptibility and gene expression.
- Author
-
Kantarci OH, Hebrink DD, Schaefer-Klein J, Sun Y, Achenbach S, Atkinson EJ, Heggarty S, Cotleur AC, de Andrade M, Vandenbroeck K, Pelfrey CM, and Weinshenker BG
- Subjects
- Alleles, Belgium epidemiology, Case-Control Studies, Enzyme-Linked Immunosorbent Assay methods, Female, Gene Frequency, Humans, Interferon-gamma metabolism, Ireland epidemiology, Linkage Disequilibrium, Male, United States epidemiology, Gene Expression genetics, Genetic Predisposition to Disease, Interferon-gamma genetics, Multiple Sclerosis genetics, Polymorphism, Single Nucleotide genetics, Sex Characteristics
- Abstract
Background: Interferon (IFN) gamma (IFNG) allelic variants are associated with susceptibility to multiple sclerosis (MS) in men but not in women., Objectives: To conduct a high-density linkage disequilibrium association study of IFNG and the surrounding region for sex-associated MS susceptibility bias and to evaluate whether IFNG allelic variants associated with MS susceptibility are associated with expression., Design: Genotype case-control study, quantitative polymerase chain reaction (qPCR), and enzyme-linked immunosorbent assay expression analyses for IFN gamma., Setting: Three independently ascertained populations from the Mayo Clinic, Rochester, Minnesota, Queen's University of Belfast, Belfast, Ireland, and University of Leuven, Leuven, Belgium., Patients: For linkage disequilibrium, 861 patients with MS (293 men and 568 women) and 843 controls (340 men and 503 women) derived from the US (population-based) and the Northern Ireland and Belgium (clinic-based) cohorts were studied. For expression analyses, 50 US patients were selected to enrich for homozygotes and to achieve a balance between men and women., Interventions: Twenty markers were genotyped over the 120-kilobase region harboring IFNG and the interleukin 26 gene (IL26)., Main Outcome Measures: Expression of IFN gamma was evaluated by qPCR and enzyme-linked immunosorbent assay in stimulated peripheral blood mononuclear cells., Results: Multiple markers were associated with MS susceptibility in men but not in women. The sex-specific susceptibility markers, of which rs2069727 was the strongest, were confined to IFNG. Carriers of rs2069727*G had higher expression than noncarriers. The effect of genotype in the qPCR experiments was also evident in men but not in women., Conclusions: IFNG is associated with sex bias in MS susceptibility and with expression of IFN gamma in MS. These observations add to a growing body of literature that implicates an interaction between sex and IFN gamma expression in a variety of disease states.
- Published
- 2008
- Full Text
- View/download PDF
216. ITGA4 polymorphisms and susceptibility to multiple sclerosis.
- Author
-
O'Doherty C, Roos IM, Antiguedad A, Aransay AM, Hillert J, and Vandenbroeck K
- Subjects
- Female, Gene Frequency, Genotype, Humans, Male, Multiple Sclerosis epidemiology, Odds Ratio, Spain epidemiology, Spain ethnology, White People, Genetic Predisposition to Disease, Integrin alpha4 genetics, Multiple Sclerosis genetics, Polymorphism, Single Nucleotide
- Abstract
In multiple sclerosis (MS), alpha(4)beta(1) integrin, also known as Very Late Antigen 4 (VLA4), facilitates migration of leukocytes across the blood brain barrier. Several studies suggest that expression of alpha(4) integrin may be increased in MS patients compared to controls, and down-regulation or antagonism of alpha(4) integrin may be associated with immunomodulatory treatment success. We analysed association of 13 single nucleotide polymorphisms (SNPs) in the gene encoding alpha(4) integrin (ITGA4) with susceptibility to MS in two distinct populations comprising cases and controls from the Basque Country in northern Spain (352 patients; 235 controls) and Nordic countries (1119 patients; 1235 controls). Carriage of the C allele of the ITGA4 promoter SNP rs1449263 was independently and weakly increased in MS patients from each population compared to respective controls (P = 0.037 in Basque; and P = 0.042 in Nordic cohorts), though these associations were lost upon application of permutation correction. Meta-analysis of rs1449263*C carriage revealed a Mantel-Haenszel common OR of 1.26 (95% CI 1.06-1.49; P = 0.0069). Though our data only modestly argue for a role of ITGA4 in determining susceptibility to MS, we suggest that further examination of this gene, particularly the promoter region, is warranted.
- Published
- 2007
- Full Text
- View/download PDF
217. Pharmacogenomics of Type I interferon therapy: a survey of response-modifying genes.
- Author
-
O'Doherty C, Villoslada P, and Vandenbroeck K
- Subjects
- Animals, Antiviral Agents pharmacology, Apoptosis, Cell Adhesion Molecules metabolism, Humans, Interferon-beta metabolism, Interferons metabolism, Lymphocyte Activation, Models, Biological, Signal Transduction, Gene Expression Regulation, Interferon Type I therapeutic use, Multiple Sclerosis genetics, Pharmacogenetics methods, Polymorphism, Genetic
- Abstract
Interferon-beta (IFN-beta) is routinely prescribed as an immunomodulatory treatment for multiple sclerosis (MS), but is associated with variable clinical efficacy. Ideally an early predictor of response status would allow more rational provision of this therapy. Both pharmacogenomic and expression analysis have highlighted IFN-beta regulated genes which may influence treatment efficacy. In this review we have summarized and discussed the main genes identified by these studies in MS patients, and supplemented this with data from similar studies of Type I IFN treatment in hepatitis.
- Published
- 2007
- Full Text
- View/download PDF
218. Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans.
- Author
-
Ban M, Booth D, Heard R, Stewart G, Goris A, Vandenbroeck K, Dubois B, Laaksonen M, Ilonen J, Alizadeh M, Edan G, Babron MC, Brassat D, Clanet M, Cournu-Rebeix I, Fontaine B, Semana G, Goedde R, Epplen J, Weber A, Infante-Duarte C, Zipp F, Rajda C, Bencsik K, Vécsei L, Heggarty S, Graham C, Hawkins S, Liguori M, Momigliano-Richiardi P, Caputo D, Grimaldi LM, Leone M, Massacesi L, Milanese C, Salvetti M, Savettieri G, Trojano M, Bielecki B, Mycko MP, Selmaj K, Santos M, Maciel P, Pereira C, Silva A, Silva BM, Coraddu F, Marrosu MG, Akesson E, Hillert J, Datta P, Oturai A, Harbo HF, Spurkland A, Goertsches R, Villoslada P, Eraksoy M, Hensiek A, Compston A, Setakis E, Gray J, Yeo TW, and Sawcer S
- Subjects
- Europe epidemiology, Female, Genotype, Humans, Jagged-1 Protein, Male, Microsatellite Repeats, Multiple Sclerosis epidemiology, Serrate-Jagged Proteins, Calcium-Binding Proteins genetics, Genetic Predisposition to Disease, Genetic Testing, Intercellular Signaling Peptides and Proteins genetics, Linkage Disequilibrium genetics, Membrane Proteins genetics, Multiple Sclerosis genetics, Trans-Activators genetics
- Abstract
By combining all the data available from the Genetic Analysis of Multiple sclerosis in EuropeanS (GAMES) project, we have been able to identify 17 microsatellite markers showing consistent evidence for apparent association. As might be expected five of these markers map within the Major Histocompatibility Complex (MHC) and are in LD with HLA-DRB1. Individual genotyping of the 12 non-MHC markers confirmed association for three of them--D11S1986, D19S552 and D20S894. Association mapping across the candidate genes implicated by these markers in 937 UK trio families revealed modestly associated haplotypes in JAG1 (p=0.019) on chromosome 20p12.2 and POU2AF1 (p=0.003) on chromosome 11q23.1.
- Published
- 2006
- Full Text
- View/download PDF
219. Celecoxib inhibits interleukin-12 alphabeta and beta2 folding and secretion by a novel COX2-independent mechanism involving chaperones of the endoplasmic reticulum.
- Author
-
Alloza I, Baxter A, Chen Q, Matthiesen R, and Vandenbroeck K
- Subjects
- Calcium physiology, Celecoxib, Cell Line, Cell Survival drug effects, Dimerization, Humans, Protein Folding, Transfection, Anti-Inflammatory Agents, Non-Steroidal pharmacology, Cyclooxygenase 2 metabolism, Endoplasmic Reticulum physiology, Interleukin-12 metabolism, Membrane Proteins metabolism, Pyrazoles pharmacology, Sulfonamides pharmacology
- Abstract
Celecoxib (CE) is a nonsteroidal anti-inflammatory drug (NSAID) that is a specific inhibitor of cyclooxygenase 2 (COX2). It is indicated for a variety of chronic inflammatory conditions, including rheumatoid arthritis. Over the last few years, adverse cardiovascular effects and increased risk for heart attacks have been associated with this drug. In addition, evidence is emerging for COX2-independent molecular targets. CE has been shown to induce apoptosis in various cancer cells lines through a COX2-independent mechanism that seems to involve inactivation of protein kinase Akt and inhibition of endoplasmic reticulum (ER) Ca2+ ATPase. In this study, we show that both CE and an analog devoid of COX2 inhibitory activity [1-(4-sulfamoyl phenyl)-3-trifluoromethyl-5-(4-trifluoromethylphenyl)pyrazole, CEA] inhibit the secretion of the dimeric interleukin-12 (IL-12) alphabeta and beta2 forms with identical IC50 values of 20 and 30 microM, respectively, whereas no such effect was seen with rofecoxib. Reverse transcription-polymerase chain reaction analysis showed that this inhibition was not due to a blockage of transcription of the alpha- and beta-chain expression cassettes. Secretion of the beta monomer form was less strongly inhibited, suggestive for a mechanism primarily targeting dimer assembly in the ER. Analysis of intracellular fractions revealed that both CE and CEA increased the association of IL-12 with calreticulin, an endoplasmic reticulum-resident chaperone involved in the retention of misfolded cargo proteins while blocking interaction with ERp44. Our findings reveal a previously undescribed effect of celecoxib on oligomer protein folding and assembly in the endoplasmic reticulum and ensuing secretion and suggest that celecoxib-driven alteration of the secretome may be involved in some of its clinical side effects.
- Published
- 2006
- Full Text
- View/download PDF
220. Multi-chaperone complexes regulate the folding of interferon-gamma in the endoplasmic reticulum.
- Author
-
Vandenbroeck K, Martens E, and Alloza I
- Subjects
- Adenosine Triphosphate chemistry, Animals, CHO Cells, Cricetinae, Endoplasmic Reticulum metabolism, Endoplasmic Reticulum Chaperone BiP, Glycosylation, Heat-Shock Proteins chemistry, Humans, Inflammation, Interleukin-10 metabolism, Jurkat Cells, Molecular Chaperones chemistry, Protein Folding, Interferon-gamma metabolism, Molecular Chaperones metabolism
- Abstract
The quality control mechanisms directing the folding of cytokines in the endoplasmic reticulum (ER) are poorly understood. We have investigated ER chaperone usage by the cytokine interferon-gamma (IFN-gamma). ATP-depletion or inhibition of N-glycosylation was found to cause IFN-gamma to accumulate into detergent-insoluble aggregates in the ER. Six chaperones, GRP94, GRP78, ERp72, PDI, CaBP1/P5 and CRT were found to associate with IFN-gamma during its steady state folding. Interaction of the five first chaperones with IFN-gamma was regulated co-ordinately by ATP. These chaperones were recently reported to be part of a multi-chaperone complex involved in the folding of complex, multi-subunit proteins. Our data suggest that also proteins with a relatively simple quaternary structure such as cytokines may fold in association with this complex. In addition, we identified calreticulin as the major chaperone interacting with IFN-gamma, and the related class II cytokine interleukin-10, during heat-shock in vivo. IFN-gamma was maintained in a folding-competent form by calreticulin during heat-shock and released during subsequent recovery at 37 degrees C. This interaction was observed in both recombinant (CHO-F11) and natural producer cells (Jurkat, NK-92MI) of IFN-gamma. Since cytokines such as IFN-gamma and IL-10 are frequently produced in the course of inflammatory conditions associated with fever, the thermo-protective effect of calreticulin may constitute a previously unrecognized component of the cellular cytokine production machinery, of likely relevance in sustaining cytokine folding and secretion in pathophysiological conditions.
- Published
- 2006
- Full Text
- View/download PDF
221. Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes.
- Author
-
Cunningham S, Graham C, Hutchinson M, Droogan A, O'Rourke K, Patterson C, McDonnell G, Hawkins S, and Vandenbroeck K
- Subjects
- Chromosome Mapping, DNA Mutational Analysis, Gene Expression drug effects, Gene Expression genetics, Genetic Testing, Genotype, Humans, Linkage Disequilibrium, Logistic Models, Polymorphism, Single Nucleotide, Treatment Outcome, Interferon-beta therapeutic use, Multiple Sclerosis genetics, Multiple Sclerosis prevention & control, Pharmacogenetics
- Abstract
Objectives: Interferon IFN-beta is indicated for the treatment of multiple sclerosis. A significant proportion of patients show a poor clinical response to therapy. Type I interferon exerts its effect at least partially through interaction of specific transcription factors with interferon-stimulated response elements (ISREs), mostly located in promoter regions of its target genes. We hypothesized that polymorphisms may occur within or close to ISRE elements, altering type I interferon inducibility and ultimately leading to a modified clinical response in carriers., Methods: We selected 100 ISRE-containing genes and sequenced their promoter regions in small genomic deoxyribonucleic acid pools of responding and nonresponding patients, as well as healthy control subjects. A selection of polymorphisms discovered by this approach was scrutinized subsequently in a collection of individual deoxyribonucleic acid samples., Results: We identified 4 genes containing polymorphisms associated with response to recombinant IFN-beta: IFNAR1 (P = .036), LMP7 (P = .002; odds ratio [OR], 6.37 [95% confidence interval (CI), 1.84-24.1]), CTSS (P = .02; OR, 0.38 [95% CI, 0.18-0.84]), and MxA (P = .015; OR, 3.37 [95% CI, 1.11-11.4]). Logistic regression analysis with treatment outcome used as the dependent variable and genotype as the independent variable revealed 2 genes, LMP7 (OR, 0.55 [95% CI, 0.34-0.89]) and MxA (OR, 0.41 [95% CI, 0.19-0.88]), that were independently associated with treatment response., Conclusions: Our work confirms and extends previous indications for a polygenic mechanism involved in bringing about responsiveness to recombinant IFN-beta. The identification of 2 genes active in the antigen processing and presentation cascade; that is, LMP7, coding for the proteasome subunit beta, and CTSS, coding for cathepsin S; as potential response modifiers may identify this pathway as being of particular relevance to phenotypic expression of response heterogeneity.
- Published
- 2005
- Full Text
- View/download PDF
222. Cross-linking approach to affinity capture of protein complexes from chaotrope-solubilized cell lysates.
- Author
-
Alloza I, Martens E, Hawthorne S, and Vandenbroeck K
- Subjects
- Calreticulin chemistry, Cell Line, Dithiothreitol, Electrophoresis, Polyacrylamide Gel, Histidine chemistry, Humans, Interleukin-12 chemistry, Nickel chemistry, Nitrilotriacetic Acid chemistry, Peptides chemistry, Plasmids, Protein Denaturation, Succinimides chemistry, Sulfhydryl Compounds, Affinity Labels, Cross-Linking Reagents, Proteins chemistry, Urea
- Abstract
Affinity capture methods are widely used for isolation and analysis of protein complexes. Short peptide tags fused to the protein of interest normally facilitate straightforward purification and detection of interacting proteins. We investigated the suitability of applying C-terminally hexahistidine-tagged interleukin-12 (IL-12) alpha- and beta-chains as "bait" proteins for cocapturing novel binding partners using heterologous recombinant human embryonic kidney-293 (HEK-293) cell lines. The beta-chain, but not the alpha-chain, extracted from cell lysates was capable of binding to the Ni(2+)-nitrilotriacetic acid affinity resin under nondenaturing conditions. Retention of the alpha-chain on this matrix was dependent on treatment of cell lysates with high concentrations of chaotropes such as urea. Since under these conditions any noncovalent protein associations are destroyed, prior cross-linking of proteins interacting with the alpha-chain in intact cells was required. The use of the thiol-cleavable cross-linker 3,3'-dithiobis(succinimidyl proprionate) facilitated dissociation of alpha-chain-binding proteins by means of dithiothreitol following purification. Using this approach we were able to demonstrate a strong interaction between the endoplasmic reticulum chaperone calreticulin (CRT) and the IL-12 alpha-chain that was confirmed in a reciprocal anti-CRT immunoprecipitation assay. The assay presented here provides a simple approach to exposing concealed hexahistidine tags while retaining native noncovalent protein interactions and should be generally applicable in a range of pull-down or affinity capture methods aiming at analysis of protein complexes.
- Published
- 2004
- Full Text
- View/download PDF
223. New candidate loci for multiple sclerosis susceptibility revealed by a whole genome association screen in a Belgian population.
- Author
-
Goris A, Sawcer S, Vandenbroeck K, Carton H, Billiau A, Setakis E, Compston A, and Dubois B
- Subjects
- Belgium epidemiology, Case-Control Studies, Cohort Studies, Female, Genetic Testing statistics & numerical data, Genetics, Population, Genotype, Humans, Linkage Disequilibrium, Male, Microsatellite Repeats, Multiple Sclerosis epidemiology, Genetic Markers, Genetic Predisposition to Disease, Genetic Testing methods, Genome, Human, Multiple Sclerosis genetics
- Abstract
We have completed a whole genome screen for association with multiple sclerosis (MS) in a Belgian population. The 6000 microsatellite markers provided through the Genetic Association of Multiple Sclerosis in EuropeanS (GAMES) collaborative were genotyped in case-control and family-based samples. The 20 most promising markers included three markers (D6S1615, D6S2444 and TNFa) from the classically established HLA class II cluster and one (D6S265) from the recently re-emphasized HLA class I cluster. In other highlighted regions, preliminary candidate genes from the immune system have been identified: e.g. the integrin ligand EDIL3, the high-mobility group box protein TOX, neutral sphingomyelinase activating factor (NSMAF) and the B-cell specific transcription factor POU2AF1.
- Published
- 2003
- Full Text
- View/download PDF
224. A genome wide scan for association with multiple sclerosis in a N. Irish case control population.
- Author
-
Heggarty S, Sawcer S, Hawkins S, McDonnell G, Droogan A, Vandenbroeck K, Hutchinson M, Setakis E, Compston A, and Graham C
- Subjects
- Adult, Alleles, Case-Control Studies, Electrophoresis, Capillary statistics & numerical data, Female, Gene Frequency, Genetic Testing statistics & numerical data, Genetics, Population methods, Genetics, Population statistics & numerical data, Genotype, Humans, International Cooperation, Male, Microsatellite Repeats, Multiple Sclerosis epidemiology, Northern Ireland epidemiology, Polymerase Chain Reaction statistics & numerical data, Genetic Predisposition to Disease, Genetic Testing methods, Genome, Human, Multiple Sclerosis genetics
- Abstract
In order to screen the genome for linkage disequilibrium (LD) in multiple sclerosis (MS), we typed 2537 microsatellite markers in separately pooled DNA from 200 cases and 200 controls from N. Ireland. Twenty two markers showing significant evidence of association were identified including three from the HLA region on chromosome 6p21. Putative candidate genes mapping close to the 19 novel markers include the IL10RA and CD3E genes on 11q23 (which both lie close to the marker D11S1998). Individual typing of the marker D11S1998 confirmed its association.
- Published
- 2003
- Full Text
- View/download PDF
225. Cytokine gene polymorphisms in multifactorial diseases: gateways to novel targets for immunotherapy?
- Author
-
Vandenbroeck K and Goris A
- Subjects
- Causality, Clinical Trials as Topic, Cytokines agonists, Cytokines antagonists & inhibitors, Humans, Interferon-gamma genetics, Interleukin-4 genetics, Cytokines genetics, Genetic Predisposition to Disease, Immunotherapy, Polymorphism, Genetic
- Abstract
Recent advances in cytokine biology have led to novel approaches to the treatment of inflammatory diseases. In this article, we review recent data regarding the role of functional polymorphisms in the genes encoding the prototypic Th1 cytokine interferon gamma and Th2 cytokine interleukin 4 in multifactorial disorders. We have compared genetic data across a heterogeneous assortment of such conditions using a 'haplotype tagging' approach, and demonstrate that cytokine gene association studies are instrumental in the identification of specific disease states or clinical manifestations that are probably caused by genetically determined aberrant cytokine expression. Some of these new findings suggest cytokine effects that go beyond a classical Th1-Th2 dichotomy. Thus, we propose that this information could provide novel targets for immunotherapy and, in particular, might facilitate the identification of clinical subgroups of patients who, by virtue of their genetic constitution at these cytokine gene loci, are more likely to benefit from cytokine agonist or antagonist therapy.
- Published
- 2003
- Full Text
- View/download PDF
226. The conserved helix C region in the superfamily of interferon-gamma /interleukin-10-related cytokines corresponds to a high-affinity binding site for the HSP70 chaperone DnaK.
- Author
-
Vandenbroeck K, Alloza I, Brehmer D, Billiau A, Proost P, McFerran N, Rüdiger S, and Walker B
- Subjects
- Amino Acid Sequence, Animals, Binding Sites, Endoplasmic Reticulum Chaperone BiP, Humans, Interferon-gamma chemistry, Interleukin-10 chemistry, Mice, Models, Molecular, Molecular Sequence Data, Sequence Homology, Amino Acid, Escherichia coli Proteins, HSP70 Heat-Shock Proteins metabolism, Interferon-gamma metabolism, Interleukin-10 metabolism
- Abstract
HSP70 chaperones mediate protein folding by ATP-dependent interaction with short linear peptide segments that are exposed on unfolded proteins. The mode of action of the Escherichia coli homolog DnaK is representative of all HSP70 chaperones, including the endoplasmic reticulum variant BiP/GRP78. DnaK has been shown to be effective in assisting refolding of a wide variety of prokaryotic and eukaryotic proteins, including the alpha-helical homodimeric secretory cytokine interferon-gamma (IFN-gamma). We screened solid-phase peptide libraries from human and mouse IFN-gamma to identify DnaK-binding sites. Conserved DnaK-binding sites were identified in the N-terminal half of helix B and in the C-terminal half of helix C, both of which are located at the IFN-gamma dimer interface. Soluble peptides derived from helices B and C bound DnaK with high affinity in competition assays. No DnaK-binding sites were found in the loops connecting the alpha-helices. The helix C DnaK-binding site appears to be conserved in most members of the superfamily of interleukin (IL)-10-related cytokines that comprises, apart from IL-10 and IFN-gamma, a series of recently discovered small secretory proteins, including IL-19, IL-20, IL-22/IL-TIF, IL-24/MDA-7 (melanoma differentiation-associated gene), IL-26/AK155, and a number of viral IL-10 homologs. These cytokines belong to a relatively small group of homodimeric proteins with highly interdigitated interfaces that exhibit the strongly hydrophobic character of the interior core of a single-chain folded domain. We propose that binding of DnaK to helix C in the superfamily of IL-10-related cytokines may constitute the hallmark of a novel conserved regulatory mechanism in which HSP70-like chaperones assist in the formation of a hydrophobic dimeric "folding" interface.
- Published
- 2002
- Full Text
- View/download PDF
227. Primitive endothelial cell lines from the porcine embryonic yolk sac.
- Author
-
Plendl J, Gilligan BJ, Wang SJ, Lewis R, Shinners B, Vandenbroeck K, and Auerbach R
- Subjects
- Animals, Endothelium, Vascular immunology, Endothelium, Vascular metabolism, Growth Hormone pharmacology, Histocompatibility Antigens immunology, Histocompatibility Antigens Class II biosynthesis, Histocompatibility Antigens Class II immunology, Interferon-gamma biosynthesis, Interferon-gamma immunology, Mice, Mice, Inbred BALB C, Mice, SCID, Swine, Transplantation, Heterologous, Cell Line, Endothelium, Vascular cytology, Yolk Sac cytology
- Abstract
Endothelial cell lines have been established from cells that were isolated from porcine yolk sacs from day 18 and day 22 embryos and propagated in vitro under various growth conditions. After expansion in vitro, the general properties of the cells proved similar for the different media used. The endothelial cells expressed cell surface receptors for acetylated low-density lipoprotein and also expressed cell surface-associated angiotensin-converting enzyme. The cells showed a characteristically high level of binding for Bandeiraea simplicifolia lectin I and Dolichos biflorus agglutinin but did not bind significant amounts of Ulex europaeus lectin I. The cells expressed low but serologically detectable levels of Class I major histocompatibility complex (MHC) antigens but failed to bind antibodies directed against Class II MHC antigens. Alpha5beta1 integrins were weakly expressed, whereas vascular cell adhesion molecule-1 (CD106) and alphavbeta3 integrins were not detected. Three-dimensional tube formation was readily observed in cultures grown on Matrigel and occurred even in uncoated plastic dishes in the absence of Matrigel. In contrast to most of the adult porcine endothelial cells, yolk sac-derived endothelial cells did not possess serologically detectable receptors for porcine growth hormone (GH), an observation consistent with the finding that GH did not increase the proliferative rate of these cells. Electron microscopic examination demonstrated the presence of Weibel-Palade bodies, tight endothelial cell junctions, and typical rough endoplasmic reticulum. Exposure of the cells to either concanavalin-A-stimulated porcine splenocyte culture supernatants or to human tumor necrosis factor alpha did not cause upregulation of VCAM-1 or Class II MHC antigens. Addition of porcine interferon-gamma led to an increase in the level of expression of Class I MHC. Yolk sac endothelial cells from day 22 embryos showed a low but detectable level of expression of Class II MHC antigens, whereas the endothelial cells from day 18 embryos showed no expression of Class II antigens after interferon-gamma stimulation. The cells maintained competence to develop vascular structures in vitro and could do so after coinjection with murine tumor cells into adult, immunocompromised mice.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.